Pimecrolimus
Product Code:
CDX-P0598
CDX-P0598
Regulatory Status:
RUO
RUO
Shipping:
AMBIENT
AMBIENT
Storage:
+4°C
+4°C
No additional charges, what you see is what you pay! *
| Code | Size | Price |
|---|
| CDX-P0598-M010 | 10 mg | £35.00 |
Quantity:
| CDX-P0598-M050 | 50 mg | £108.00 |
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: Switzerland.
Typical lead time: 7-10 working days.
Contact us for more accurate information.
Typical lead time: 7-10 working days.
Contact us for more accurate information.
- Further Information
- Documents
- References
- Show All
Further Information
Alternate Names/Synonyms:
Elidel; SDZ-ASM 981; 33-Epichloro-33-desoxyascomycin
Appearance:
White to beige powder.
CAS:
137071-32-0
EClass:
32160000
Form (Short):
liquid
Handling Advice:
Protect from light and moisture.
InChi:
InChI=1S/C43H68ClNO11/c1-10-30-18-24(2)17-25(3)19-36(53-8)39-37(54-9)21-27(5)43(51,56-39)40(48)41(49)45-16-12-11-13-32(45)42(50)55-38(28(6)33(46)23-34(30)47)26(4)20-29-14-15-31(44)35(22-29)52-7/h18,20,25,27-33,35-39,46,51H,10-17,19,21-23H2,1-9H3/b24-18+,26-20+/t25-,27+,28+,29-,30+,31-,32-,33-,35+,36-,37-,38+,39+,43+/m0/s1
InChiKey:
KASDHRXLYQOAKZ-XDSKOBMDSA-N
Long Description:
Chemical. CAS: 137071-32-0. Formula: C43H68ClNO11. MW: 810.45. Synthetic. Pimecrolimus is a immunosuppressive natural ascomycin macrolactam that binds to macrophilin-12 (FKBP-12) and inhibits calcineurin as well as prolyl isomerase (rotamase). Presumably through these actions, it blocks the activation of T cells by allogeneic dendritic cells (IC50=0.55nM) without affecting dendritic cells. Moreover, pimecrolimus suppresses the generation of pro-inflammatory cytokines by T cells, the release of pre-formed inflammatory mediators from mast cells and the activation of eosinophils. These effects support the use of pimecrolimus in countering inflammatory skin diseases, such as atopic dermatitis (eczema) and psoriasis.
MDL:
MFCD00901792
Molecular Formula:
C43H68ClNO11
Molecular Weight:
810.45
Package Type:
Vial
Product Description:
Pimecrolimus is a immunosuppressive natural ascomycin macrolactam that binds to macrophilin-12 (FKBP-12) and inhibits calcineurin as well as prolyl isomerase (rotamase). Presumably through these actions, it blocks the activation of T cells by allogeneic dendritic cells (IC50=0.55nM) without affecting dendritic cells. Moreover, pimecrolimus suppresses the generation of pro-inflammatory cytokines by T cells, the release of pre-formed inflammatory mediators from mast cells and the activation of eosinophils. These effects support the use of pimecrolimus in countering inflammatory skin diseases, such as atopic dermatitis (eczema) and psoriasis.
Purity:
>97% (HPLC)
SMILES:
Cl[C@@H]1[C@@H](C[C@@H](CC1)/C=C(C)/[C@H]([C@H](C)[C@H](C2)O)OC([C@H](CCCC3)N3C(C([C@@](O)([C@H](C)C4)O[C@H]([C@H](C[C@@H](C)C/C(C)=C/[C@@H](CC)C2=O)OC)[C@H]4OC)=O)=O)=O)OC
Solubility Chemicals:
Soluble in DMSO (20mg/ml), DMF (20mg/ml) or ethanol (20mg/ml).
Source / Host:
Synthetic
Transportation:
Non-hazardous
UNSPSC Category:
Natural Products/Extracts
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at +4°C.
Documents
References
(1) D. Bochelen, et al.; J. Pharmacol. Exp. Therap. 288, 653 (1999) | (2) M. Grassberger, et al.; Br. J. Dermatol. 141, 264 (1999) | (3) T. Zuberbier, et al.; J. All. Clin. Immunol. 108, 275 (2001) | (4) F.S. Kalthoff, et al.; Clin. Exp. Immunol. 130, 85 (2002) | (5) K. Rappersberger, et al.; J. Invest. Dematol. 119, 876 (2002) | (6) J.G. Meingassner, et al.; J. Invest. Dermatol. 121, 77 (2003) | (7) F.S. Kalthoff, et al.; Clin. Exp. Immunol. 133, 350 (2003) | (8) J.G. Meingassner, et al.; Br. J. Dermatol. 149, 853 (2003) | (9) D.A. Plager, et al.; Int. Arch. Allergy Immunol. 149, 119 (2009) | (10) Z. Ma & Z. Jiao; Curr. Pharm. Des. 17, 3823 (2011) (Review) | (11) S.G. Danby & M.J. Cork; Br. J. Dermatol. 168, 235 (2013)